J Clin Endocrinol Metab

Caffeine intake and cardiometabolic multimorbidity: What’s the association?

September 20, 2024

Moderate coffee or caffeine intake is associated with a lower risk of developing new-onset cardiometabolic multimorbidity (CM) and may be beneficial during various stages of CM development. Authors call for future research to confirm the metabolic biomarkers involved in the relationship between coffee, tea, caffeine intake, and CM.

• This prospective study included 172,315 (for caffeine analysis) and 188,091 (tea and coffee analysis) participants free of any CM diseases at baseline from the UK Biobank; 168 metabolites were measured among 88,204 and 96,393 participants. CM was defined as the coexistence of ≥2 of the following conditions: T2DM, coronary heart disease, and stroke.
• Nonlinear inverse associations of coffee, tea, and caffeine intake with the risk of new-onset CM were observed. Consumers of a moderate amount of coffee (3 drinks/day) or caffeine (200-300 mg/day) had the lowest risk for new-onset CM compared with nonconsumers or consumers of <100 mg of caffeine/day, with respective hazard ratios of 0.519 and 0.593.
• Inverse associations were seen for moderate coffee or caffeine intake with the risks for almost all developmental stages of CM, including transitions from a disease-free state to single CM diseases and subsequently to CM. A total of 80 to 97 metabolites, such as lipid components within very low-density lipoprotein, histidine, and glycoprotein acetyls, were identified to be associated with both coffee, tea, or caffeine intake and incident CM.

Source:

Lu X, et al. (2024, September 17). J Clin Endocrinol Metab. Habitual Coffee, Tea, and Caffeine Consumption, Circulating Metabolites, and the Risk of Cardiometabolic Multimorbidity. https://pubmed.ncbi.nlm.nih.gov/39287934/